Immunomodulation with IL-7 and IL-15 in HIV-1 infection
Immunomodulating agents are substances that modify the host immune responses in diseases such as infections, autoimmune conditions and cancers. Immunomodulators can be divided into two main groups: 1) immunostimulators that activate the immune system such as cytokines, toll-like receptor agonists an...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Journal of Virus Eradication |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S205566402300033X |
| _version_ | 1797672773967937536 |
|---|---|
| author | Jesper D. Gunst Nilu Goonetilleke Thomas A. Rasmussen Ole S. Søgaard |
| author_facet | Jesper D. Gunst Nilu Goonetilleke Thomas A. Rasmussen Ole S. Søgaard |
| author_sort | Jesper D. Gunst |
| collection | DOAJ |
| description | Immunomodulating agents are substances that modify the host immune responses in diseases such as infections, autoimmune conditions and cancers. Immunomodulators can be divided into two main groups: 1) immunostimulators that activate the immune system such as cytokines, toll-like receptor agonists and immune checkpoint blockers; and 2) immunosuppressors that dampen an overactive immune system such as corticosteroids and cytokine-blocking antibodies. In this review, we have focussed on the two primarily T and natural killer (NK) cell homeostatic cytokines: interleukin-7 (IL-7) and -15 (IL-15). These cytokines are immunostimulators which act on immune cells independently of the presence or absence of antigen. In vivo studies have shown that IL-7 administration enhances proliferation of circulating T cells whereas IL-15 agonists enhance the proliferation and function of NK and CD8+ T cells. Both IL-7 and IL-15 therapies have been tested as single interventions in HIV-1 cure-related clinical trials. In this review, we explore whether IL-7 and IL-15 could be part of the therapeutic approaches towards HIV-1 remission. |
| first_indexed | 2024-03-11T21:35:06Z |
| format | Article |
| id | doaj.art-af0b63c324924902a4aae5296409d05f |
| institution | Directory Open Access Journal |
| issn | 2055-6640 |
| language | English |
| last_indexed | 2024-03-11T21:35:06Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Virus Eradication |
| spelling | doaj.art-af0b63c324924902a4aae5296409d05f2023-09-27T04:42:41ZengElsevierJournal of Virus Eradication2055-66402023-09-0193100347Immunomodulation with IL-7 and IL-15 in HIV-1 infectionJesper D. Gunst0Nilu Goonetilleke1Thomas A. Rasmussen2Ole S. Søgaard3Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Corresponding author. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.Department of Microbiology & Immunology, University of North Carolina, Chapel Hill, North Carolina, USA; Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USADepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, DenmarkImmunomodulating agents are substances that modify the host immune responses in diseases such as infections, autoimmune conditions and cancers. Immunomodulators can be divided into two main groups: 1) immunostimulators that activate the immune system such as cytokines, toll-like receptor agonists and immune checkpoint blockers; and 2) immunosuppressors that dampen an overactive immune system such as corticosteroids and cytokine-blocking antibodies. In this review, we have focussed on the two primarily T and natural killer (NK) cell homeostatic cytokines: interleukin-7 (IL-7) and -15 (IL-15). These cytokines are immunostimulators which act on immune cells independently of the presence or absence of antigen. In vivo studies have shown that IL-7 administration enhances proliferation of circulating T cells whereas IL-15 agonists enhance the proliferation and function of NK and CD8+ T cells. Both IL-7 and IL-15 therapies have been tested as single interventions in HIV-1 cure-related clinical trials. In this review, we explore whether IL-7 and IL-15 could be part of the therapeutic approaches towards HIV-1 remission.http://www.sciencedirect.com/science/article/pii/S205566402300033X |
| spellingShingle | Jesper D. Gunst Nilu Goonetilleke Thomas A. Rasmussen Ole S. Søgaard Immunomodulation with IL-7 and IL-15 in HIV-1 infection Journal of Virus Eradication |
| title | Immunomodulation with IL-7 and IL-15 in HIV-1 infection |
| title_full | Immunomodulation with IL-7 and IL-15 in HIV-1 infection |
| title_fullStr | Immunomodulation with IL-7 and IL-15 in HIV-1 infection |
| title_full_unstemmed | Immunomodulation with IL-7 and IL-15 in HIV-1 infection |
| title_short | Immunomodulation with IL-7 and IL-15 in HIV-1 infection |
| title_sort | immunomodulation with il 7 and il 15 in hiv 1 infection |
| url | http://www.sciencedirect.com/science/article/pii/S205566402300033X |
| work_keys_str_mv | AT jesperdgunst immunomodulationwithil7andil15inhiv1infection AT nilugoonetilleke immunomodulationwithil7andil15inhiv1infection AT thomasarasmussen immunomodulationwithil7andil15inhiv1infection AT olessøgaard immunomodulationwithil7andil15inhiv1infection |